Method Profile
Combine subtype-specific mucin imaging and tumor characterization with a chemotherapy concentration-response panel.
Investigate pharmacological differences among mucinous gastric tumors and between matched primary and metastatic tissue.
Four mucinous gastric cancer organoid models from three patients, including one matched primary–peritoneal-metastasis pair.
72-hour CellTiter-Glo 2.0 ATP-associated viability across an 11-agent panel, with histology, marker staining and live mucin imaging.
Models
MGC-T, MGC-ND, MGC2 and MGC3, with six nonmucinous organoid comparators.
Drug panel
Fluorouracil, oxaliplatin, taxanes and other chemotherapy agents.
Subtype characterization
Mucin staining and imaging, epithelial markers and matched tumor sections.
Viability measurement
CellTiter-Glo 2.0 luminescence after 72 hours, normalized to DMSO controls. The standard reagent is optimized for two-dimensional cultures.
Compare drug classes within each model and preserve the distinction between model-level testing and the mixed-histology clinical subset.
Drug concentration responses and an exploratory clinical association.
Four mucinous models; technical triplicates and three independent experiments; eight clinical cases comprising six nonmucinous and two mucinous tumors.
Matched primary/metastatic models and nonmucinous gastric organoids.
Mucinous models retained mucin behavior and showed taxane sensitivity; clinical agreement for oxaliplatin–fluorouracil was 7/8.
Four organoid models from three patients retained features of mucinous gastric cancer. Drug testing revealed differences between chemotherapy classes and between a primary tumor and its matched metastasis.
